Cure My Disease

Don't miss your cure!

 Log in / Sign up

CAR-T cells take on progressive MS: early trial launches

NCT ID NCT06675864

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This early-phase trial tests a single dose of YTB323, a CAR-T cell therapy, in 28 adults with non-active progressive multiple sclerosis. The study aims to check safety and track disability changes over time. Participants must be 18–60 and able to undergo lumbar punctures and MRIs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
YTB323 (rapcabtagene autoleucel), a CAR-T cell therapy
What this could lead to
If it works, this could point toward a new way to slow or stop disability worsening in progressive multiple sclerosis.
What could go wrong
This is an early phase 1/2 study with only 28 participants, so results may not apply broadly. CAR-T therapies carry risks like cytokine release syndrome and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROGRESSIVE MULTIPLE SCLEROSIS

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Darlinghurst, New South Wales, 2010, Australia

  • Novartis Investigative Site

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Novartis Investigative Site

    RECRUITING

    Québec, Quebec, G1J 1Z4, Canada

  • Novartis Investigative Site

    RECRUITING

    Bron, 69677, France

  • Novartis Investigative Site

    RECRUITING

    Montpellier, 34090, France

  • Novartis Investigative Site

    RECRUITING

    Nancy, 54035, France

  • Novartis Investigative Site

    RECRUITING

    Rennes, 35033, France

  • Novartis Investigative Site

    RECRUITING

    Essen, 45147, Germany

  • Novartis Investigative Site

    RECRUITING

    Mainz, 55131, Germany

  • Novartis Investigative Site

    RECRUITING

    Ulm, 89081, Germany

  • Novartis Investigative Site

    RECRUITING

    Genova, GE, 16132, Italy

  • Novartis Investigative Site

    RECRUITING

    Milan, MI, 20132, Italy

  • Novartis Investigative Site

    RECRUITING

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28222, Spain

  • Novartis Investigative Site

    RECRUITING

    Málaga, 29010, Spain

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Bern, 3010, Switzerland

  • Novartis Investigative Site

    RECRUITING

    Lausanne, 1011, Switzerland

  • Novartis Investigative Site

    RECRUITING

    Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.